Long-Term Propensity-Matched Comparison of Fenestrated Endovascular Aneurysm Repair and Open Surgical Repair of Complex Abdominal Aortic Aneurysms.
Giovanni Tinelli, Simona Sica, Jonathan Sobocinski...
https://pubmed.ncbi.nlm.nih.gov/36978269/Actively Recruiting
Led by Bolton Medical · Updated on 2026-02-18
20
Participants Needed
7
Research Sites
156 weeks
Total Duration
Researchers are evaluating the Fenestrated TREO Stent-Graft System as a treatment for adults with a specific type of abdominal aneurysm called a juxtarenal abdominal aortic aneurysm. This condition involves a bulge in the main blood vessel the aorta in the abdomen, and the study aims to learn if this device can safely and effectively treat these aneurysms. The study is a prospective, multicenter, non-blinded, non-randomized pivotal trial sponsored by Bolton Medical. Participants will undergo implantation of the Fenestrated TREO Stent-Graft System through an endovascular surgical procedure. This modular device includes a main body fenestrated bifurcate stent-graft, bridging stents to connect to target visceral arteries, and leg and straight extension stent-grafts to cover the aneurysm area. The trial plans to enroll a minimum of 20 and up to 30 participants with juxtarenal abdominal aortic aneurysms. After the procedure, participants will be followed up for five years with regular checkups, tests, and imaging scans. During the study, participants will attend visits at discharge, 30 days, six months, 12 months, and annually through five years after implant. Researchers will monitor safety by tracking major adverse events within 30 days and evaluate effectiveness by assessing successful aneurysm treatment up to 12 months post-procedure. Technical success of device delivery will also be measured at 30 days. Additional assessments include monitoring mortality, heart and respiratory events, kidney function, strokes, aneurysm-related complications, device performance, and other health outcomes throughout the follow-up period.
CONDITIONS
Endovascular Repair With Fenestrated TREO Stent-Graft System in AAA
L
Lauren Rider
V
Valerie Merkle
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Bolton Medical
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Endovascular Repair with Fenestrated TREO Stent-Graft | Open Surgical Repair |
|---|---|---|
| What it is | A modular fenestrated stent-graft system delivered endovascularly to seal abdominal aortic aneurysms involving or near the renal and visceral arteries while maintaining blood flow to essential branch vessels. | A traditional surgical procedure through a large abdominal incision to replace the aneurysmal segment with a synthetic graft, requiring temporary interruption of the aorta near vital arteries. |
| Primary use | Minimally invasive treatment of complex abdominal aortic aneurysms that are not suitable for standard endovascular grafts due to involvement of renal or visceral arteries. | Definitive surgical repair for anatomically complex abdominal aortic aneurysms, historically considered the standard approach for aneurysms near vital branches. |
| How it is given or performed | Device introduced through a femoral artery incision using wires and catheters under imaging guidance; precise placement aligns fenestrations with branch arteries, followed by placement of bridging stents and completion of repair with leg extensions. | Surgical exposure of the abdominal aorta under general anesthesia; the aneurysm is opened, the diseased aorta excised, and a synthetic graft is sewn in to replace it, generally requiring temporary aortic cross-clamping. |
| Evidence status | Current evidence for safety and effectiveness from prospective studies is still in progress, with outcomes including survival without major adverse events and technical success under investigation. | Decades of data show open repair is a definitive treatment, with contemporary matched studies showing perioperative mortality rates of 5–10% and long-term durability in complex AAA populations. |
| Important limitations | Candidate anatomy must be suitable for fenestrated device design and technical success is dependent on precise alignment with visceral arteries; device outcomes for this system in complex aneurysms remain under investigation. | Open repair is associated with higher perioperative risk, increased length of hospital stay and slower recovery, especially in older patients or those with significant comorbidities. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Procedure day
Participants undergo endovascular repair of abdominal aortic aneurysms using the Fenestrated TREO Stent-Graft System.
1 procedure visit (in-person)
Duration - Until discharge
Participants receive post-operative monitoring immediately after the stent-graft implant procedure.
1 to 2 visits (in-person) around hospital discharge
Duration - Up to 5 years post-procedure
Participants attend scheduled follow-up visits to monitor safety, device performance, and aneurysm status through 12 months and annually up to 5 years post-procedure.
Visits at discharge, 30 days, 6 months, 12 months, and annually thereafter
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Giovanni Tinelli, Simona Sica, Jonathan Sobocinski...
https://pubmed.ncbi.nlm.nih.gov/36978269/K K Yeung, J H Nederhoed, B L Tran...
https://pubmed.ncbi.nlm.nih.gov/38288587/Gustavo S Oderich, Thomas L Forbes, Rabih Chaer...
https://pubmed.ncbi.nlm.nih.gov/32615285/Christopher A Latz, Laura Boitano, Samuel Schwartz...
https://pubmed.ncbi.nlm.nih.gov/33046385/Mark F Fillinger, Roy K Greenberg, James F McKinsey...
https://pubmed.ncbi.nlm.nih.gov/20888533/Sara L Zettervall, Benjamin W Starnes
https://pubmed.ncbi.nlm.nih.gov/36153066/Lorenz Meuli, Yves L Kaufmann, Thomas Lattmann...
https://pubmed.ncbi.nlm.nih.gov/38906370/Issam D Moussa, Lloyd W Klein, Binita Shah...
https://pubmed.ncbi.nlm.nih.gov/24135581/Benjamin W Starnes, Sara Zettervall, Allison Larimore...
https://pubmed.ncbi.nlm.nih.gov/38920026/Lesley A Inker, Brad C Astor, Chester H Fox...
https://pubmed.ncbi.nlm.nih.gov/24647050/Bolton Medical
Lead Sponsor